Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06265272 · ClinicalTrials.gov registry record
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A clinical trial of Liver Cirrhosis and Portal Hypertension, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06265272: Recruiting study of Liver Cirrhosis and Portal Hypertension, sponsored by Massachusetts General Hospital.
NCT06265272 is a study of Liver Cirrhosis and Portal Hypertension that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06265272, a study of Liver Cirrhosis and Portal Hypertension, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
Primary Outcome
PET, MRI, and fused PET/MRI images will be evaluated to determine the effect of contrast-enhanced Ga-PSMA/PETMRI on evaluating liver nodules. Images will be evaluated at least 4 weeks apart from each other to reduce recall bias. Each lesion described by the readers of the imaging modalities will then be classified accordingly into true positive, false positive, true negative, or false negative. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value will then
Conditions Studied
Interventions
- DRUG Injection of a gadolinium contrast agen
- DRUG Radiotracer Injection
- DIAGNOSTIC_TEST Imaging
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-10 |
| Est. Completion | 2026-12-19 |
What NCT06265272 shows while recruiting
NCT06265272 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Liver Cirrhosis appearing as the primary indexed condition, and to 3 interventions - of which Injection of a gadolinium contrast agen is the first listed.
NCT06265272 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06265272 about?
NCT06265272 is a clinical study titled "Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis". A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro an...
What is the current status of trial NCT06265272?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2023-12-10. Estimated completion is 2026-12-19.
What conditions does trial NCT06265272 study?
This clinical trial studies the following conditions: Liver Cirrhosis, Portal Hypertension, Hepatic Cell Carcinoma.
What interventions are being tested in trial NCT06265272?
The interventions under investigation include: Injection of a gadolinium contrast agen (DRUG), Radiotracer Injection (DRUG), Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06265272?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06265272 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06265272's enrollment target sits among peer trials
45 12th of 15 higher than 4 of 15 other Liver Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
RECRUITING · Phase 2
-
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
RECRUITING
-
Steroid Free Immunosuppression in Liver Transplantation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI